Q1 Earnings Forecast for Surrozen Issued By Lifesci Capital

Surrozen, Inc. (NASDAQ:SRZN) – Research analysts at Lifesci Capital reduced their Q1 2026 earnings per share (EPS) estimates for Surrozen in a report issued on Monday, March 23rd. Lifesci Capital analyst P. Dolezal now anticipates that the company will post earnings of ($2.06) per share for the quarter, down from their prior forecast of ($1.82). The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. Lifesci Capital also issued estimates for Surrozen’s Q2 2026 earnings at ($2.10) EPS, Q3 2026 earnings at ($2.17) EPS, Q4 2026 earnings at ($1.23) EPS and FY2026 earnings at ($4.73) EPS.

Several other brokerages have also weighed in on SRZN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $36.00 target price (up from $32.00) on shares of Surrozen in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Surrozen from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Surrozen Stock Performance

Shares of NASDAQ SRZN opened at $28.90 on Thursday. The business has a 50 day simple moving average of $24.67 and a 200 day simple moving average of $19.00. Surrozen has a 52 week low of $5.90 and a 52 week high of $29.59. The stock has a market cap of $247.70 million, a price-to-earnings ratio of -0.87 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The firm had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%.

Institutional Trading of Surrozen

A number of institutional investors and hedge funds have recently modified their holdings of SRZN. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares during the period. Stonepine Capital Management LLC raised its holdings in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after acquiring an additional 20,247 shares during the period. Stempoint Capital LP lifted its position in Surrozen by 185.1% during the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares during the last quarter. Armistice Capital LLC acquired a new position in Surrozen during the 2nd quarter worth $536,000. Finally, Braidwell LP bought a new stake in Surrozen during the second quarter valued at about $1,252,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Surrozen

In related news, major shareholder Group Gp Lp Column III bought 18,052 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the insider directly owned 1,016,658 shares of the company’s stock, valued at $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Tim Kutzkey purchased 18,052 shares of the stock in a transaction on Tuesday, January 20th. The shares were bought at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the acquisition, the director owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 330,291 shares of company stock valued at $7,478,785. Corporate insiders own 45.18% of the company’s stock.

More Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buying: TCG Crossover GP II purchased 106,658 shares on March 24 (~$2.63M at ~$24.69) as part of a recent string of purchases, materially increasing its stake and signaling insider conviction that can support the stock. InsiderTrades: Major Shareholder Purchases
• Positive Sentiment: Follow-on insider buy: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90 (SEC filing disclosed), reinforcing the same insider-buy signal. American Banking News: Tcg Crossover Acquires Shares
• Positive Sentiment: Analyst support: Cantor Fitzgerald gave an “Overweight” rating and a $40 target, and HC Wainwright reiterated a “Buy” and raised targets/longer-term EPS forecasts — both items tend to attract buyer interest and can lift sentiment. American Banking News: Cantor Fitzgerald Rating American Banking News: HC Wainwright Buy Rating
• Positive Sentiment: HC Wainwright commentary on FY2030 shows a materially less-negative multi-year EPS path in their model (raises to FY2026–FY2029/FY2030 estimates), suggesting improving operating/profitability assumptions versus consensus. American Banking News: HC Wainwright FY2030 Comments
• Neutral Sentiment: Short-interest / days-to-cover data in some reports appears inconsistent (some sources show zero shorts / NaN), so treat short-interest as unreliable in explaining the move today.
• Negative Sentiment: Lifesci Capital cut near-term EPS estimates across Q1–Q4 2026 and trimmed FY2026, signaling more conservative short-term cash/burn or program timing assumptions — a reminder of execution and cash-risk that could cap upside. MarketBeat: Analyst Estimate Changes

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.